ReFlections

In this Expert Q&A from RGA's ReFlections newsletter, Dr. Daniel D. Zimmerman sits down with David Sinclair, CEO of the International Longevity Centre UK, to discuss the challenges presented by aging populations, the importance of promoting healthsp...

Studies strongly suggest a link between exposure to BPA and reproductive disorders, certain cancers, metabolic dysfunction, and neurodevelopmental disorders in children. 

Pediatric overweight and obesity has made a significant presence worldwide and presents a critical public health challenge. In this article from RGA's 

Explore in-depth articles on important medical topics and stay up to date on a range of hot-button issues impacting life and health insurers, from the health impacts of Bisphenol A (BPA) to considerations around GLP-1 drugs.

This article, the second of two

During a recent conversation with Dr. Dan Zimmerman from RGA’s ReFlections newsletter, RGA Genetics Consultant Dr. Sajel Lala Kana offers detailed insights in...

The modern environment constantly encourages people to eat more calories than they expend. In this article from RGA's 

Borderline ovarian tumors (BOT) can cause confusion for claims assessors. In this article from RGA's 

Explore in-depth articles on important medical topics and stay up to date on a range of hot-button issues impacting life and health insurers, from the obesity epidemic to AI’s role in healthcare. 

In this article from RGA's ReFlections newsletter, Dr. Heather Lund explores the mechan...

It is important for insurers to understand potential causes, such as high ultra-processed food (UPF) consumption, behind rising rates of non-communicable diseases. In this article from RGA's

The World Health Organization (WHO) estimates that by the year 2030 – less than 10 years from now – about 78 million people will be living with dementia. This number is projected to nearly double, to 139 million, by 2050.¹ This article from RGA's

Features in this issue of ReFlections explore PCSK-9 inhibitors and...

Explore the sequelae of long COVID, the range genetic therapies designed to target certain cancers, and developments in cystic fibrosis.